Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance.

ABSTRACT:

Background

In breast cancer, overexpression of the transmembrane tyrosine kinase ERBB2 is an adverse prognostic marker, and occurs in almost 30% of the patients. For therapeutic intervention, ERBB2 is targeted by monoclonal antibody trastuzumab in adjuvant settings; however, de novo resistance to this antibody is still a serious issue, requiring the identification of additional targets to overcome resistance. In this study, we have combined computational simulations, experimental testing of simulation results, and finally reverse engineering of a protein interaction network to define potential therapeutic strategies for de novo trastuzumab resistant breast cancer.

Results

First, we employed Boolean logic to model regulatory interactions and simulated single and multiple prot

SUBMITTER: Sahin O 

PROVIDER: S-EPMC2652436 | biostudies-literature | 2009 Jan

REPOSITORIES: biostudies-literature